For instance, in AML, the oncometabolite 2-hydroxyglutarate (2-HG) generated by IDH1/2 mutations competes with α-ketoglutarate (α-KG) for binding, leading to extensive methylation of DNA and histones, disrupting crucial hematopoietic signaling pathways and facilitating the onset of AML (15). This evidence concerns the gene IDH1 and acute myeloid leukemia.